138 related articles for article (PubMed ID: 34951962)
1. Roles of MET in human cancer.
Yang X; Liao HY; Zhang HH
Clin Chim Acta; 2022 Jan; 525():69-83. PubMed ID: 34951962
[TBL] [Abstract][Full Text] [Related]
2. Expression of hepatocyte growth factor and the proto-oncogenic receptor c-Met in canine osteosarcoma.
Fieten H; Spee B; Ijzer J; Kik MJ; Penning LC; Kirpensteijn J
Vet Pathol; 2009 Sep; 46(5):869-77. PubMed ID: 19429984
[TBL] [Abstract][Full Text] [Related]
3. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit.
Ferracini R; Di Renzo MF; Scotlandi K; Baldini N; Olivero M; Lollini P; Cremona O; Campanacci M; Comoglio PM
Oncogene; 1995 Feb; 10(4):739-49. PubMed ID: 7862451
[TBL] [Abstract][Full Text] [Related]
4. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma.
Coltella N; Manara MC; Cerisano V; Trusolino L; Di Renzo MF; Scotlandi K; Ferracini R
FASEB J; 2003 Jun; 17(9):1162-4. PubMed ID: 12709413
[TBL] [Abstract][Full Text] [Related]
5. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
Christensen JG; Burrows J; Salgia R
Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-101-3p suppresses proliferation and migration in hepatocellular carcinoma by targeting the HGF/c-Met pathway.
Liu Y; Tan J; Ou S; Chen J; Chen L
Invest New Drugs; 2020 Feb; 38(1):60-69. PubMed ID: 30929159
[TBL] [Abstract][Full Text] [Related]
8. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
[TBL] [Abstract][Full Text] [Related]
9. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
[TBL] [Abstract][Full Text] [Related]
10. Involvement of c-Met/hepatocyte growth factor pathway in cholangiocarcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for c-Met.
Leelawat K; Leelawat S; Tepaksorn P; Rattanasinganchan P; Leungchaweng A; Tohtong R; Sobhon P
J Surg Res; 2006 Nov; 136(1):78-84. PubMed ID: 16950403
[TBL] [Abstract][Full Text] [Related]
11. miR-454 is down-regulated in osteosarcomas and suppresses cell proliferation and invasion by directly targeting c-Met.
Niu G; Li B; Sun J; Sun L
Cell Prolif; 2015 Jun; 48(3):348-55. PubMed ID: 25880599
[TBL] [Abstract][Full Text] [Related]
12. Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells.
Navab R; Liu J; Seiden-Long I; Shih W; Li M; Bandarchi B; Chen Y; Lau D; Zu YF; Cescon D; Zhu CQ; Organ S; Ibrahimov E; Ohanessian D; Tsao MS
Neoplasia; 2009 Dec; 11(12):1292-300. PubMed ID: 20019837
[TBL] [Abstract][Full Text] [Related]
13. Aberrant expression of hepatocyte growth factor and its receptor, c-Met, during sex hormone-induced prostatic carcinogenesis in the Noble rat.
Tam NN; Chung SS; Lee DT; Wong YC
Carcinogenesis; 2000 Dec; 21(12):2183-91. PubMed ID: 11133807
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-876-5p inhibits cell proliferation, migration and invasion by targeting c-Met in osteosarcoma.
Xie W; Xiao J; Wang T; Zhang D; Li Z
J Cell Mol Med; 2019 May; 23(5):3293-3301. PubMed ID: 30773847
[TBL] [Abstract][Full Text] [Related]
15. SOX9 in prostate cancer is upregulated by cancer-associated fibroblasts to promote tumor progression through HGF/c-Met-FRA1 signaling.
Qin H; Yang Y; Jiang B; Pan C; Chen W; Diao W; Ding M; Cao W; Zhang Z; Chen M; Gao J; Zhao X; Qiu X; Guo H
FEBS J; 2021 Sep; 288(18):5406-5429. PubMed ID: 33705609
[TBL] [Abstract][Full Text] [Related]
16. The potential therapeutic and prognostic impacts of the c-MET/HGF signaling pathway in colorectal cancer.
Parizadeh SM; Jafarzadeh-Esfehani R; Fazilat-Panah D; Hassanian SM; Shahidsales S; Khazaei M; Parizadeh SMR; Ghayour-Mobarhan M; Ferns GA; Avan A
IUBMB Life; 2019 Jul; 71(7):802-811. PubMed ID: 31116909
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma.
Suzuki Y; Sakai K; Ueki J; Xu Q; Nakamura T; Shimada H; Nakamura T; Matsumoto K
Int J Cancer; 2010 Oct; 127(8):1948-57. PubMed ID: 20104519
[TBL] [Abstract][Full Text] [Related]
18. The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies.
Børset M; Seidel C; Hjorth-Hansen H; Waage A; Sundan A
Leuk Lymphoma; 1999 Jan; 32(3-4):249-56. PubMed ID: 10037022
[TBL] [Abstract][Full Text] [Related]
19. MiR-133b is down-regulated in human osteosarcoma and inhibits osteosarcoma cells proliferation, migration and invasion, and promotes apoptosis.
Zhao H; Li M; Li L; Yang X; Lan G; Zhang Y
PLoS One; 2013; 8(12):e83571. PubMed ID: 24391788
[TBL] [Abstract][Full Text] [Related]
20. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.
Torres KE; Zhu QS; Bill K; Lopez G; Ghadimi MP; Xie X; Young ED; Liu J; Nguyen T; Bolshakov S; Belousov R; Wang S; Lahat G; Liu J; Hernandez B; Lazar AJ; Lev D
Clin Cancer Res; 2011 Jun; 17(12):3943-55. PubMed ID: 21540237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
